In a recent article published in CGTLive, Cartherics’ Prof. Alan Trounson, Karl Trounson, Dr Walid Azar and Prof. Richard Boyd, together with Dr. Alice Pebay, Principal Research Fellow, The University of Melbourne and Royal Melbourne Hospital – discuss exciting developments in immunotherapy with natural killer (NK) cells.
As the cell therapy landscape continues to evolve, NK […]
Melbourne, Australia, 18 December 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for cancer treatment. The article discusses:
Melbourne, Australia, 1 October 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a […]
In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work in developing cell therapy treatments for cancer. He discusses Cartherics’ expanding intellectual property portfolio, the impact of targeting TAG-72 on treating ovarian and gastric cancers as well as recent collaborations and the growing market for […]
Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically modified cells and uses thereof”, providing patent support for multiple development candidates in the […]
Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.
The European Patent No. 3708587 B1, titled ‘Genetically […]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics’ innovative approach to using stem cells to develop new cancer therapies. Alan’s leadership and expertise underscore the company’s commitment to advancing cancer treatment and improving outcomes for patients. Read the article here: https://pulse2.com/cartherics-prof-alan-trounson-profile/
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
